Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauder for supplementing monograph

This article was originally published in The Rose Sheet

Executive Summary

Sunscreen ingredients bemotrizinol and bisoctrizole should be added to FDA's OTC sunscreen monograph, Estee Lauder asserts in Nov. 1 comments to the agency, in support of time and extent applications filed by Ciba in April 2005. After reviewing the applications, FDA recommended initially that both ingredients (up to 10% each) be recommended for monograph inclusion. Then in a Dec. 5 Federal Register notice, the agency issued a call for data on bemotrizinol and bisoctrizole as single active ingredients and in combination with other active ingredients in sunscreen products (1"The Rose Sheet" Dec. 12, 2005, p. 3). "The Lauder Companies would like to offer our consumers more broad-spectrum, photostable UVA protective sunscreen products that will protect them from both UVA and UVB," Lauder states, adding: "We petition you to approve these sunscreen actives as soon as possible"...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014389

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel